Albuminuria-based stratification of end-stage kidney disease progression and mortality with sodium-glucose cotransporter 2 inhibitors (SGLT2i): A retrospective cohort study in type 2 diabetes and chronic kidney disease

• Published in: Pharmacotherapy Vol. 44; no. 11; p. 828
• Main Authors: Chang, Tien-Jyun, Lee, Yen-Chieh, Wu, Li-Chiu, Chang, Chia-Hsuin
• Format: Journal Article
• Language: English
• Published: United States 01.11.2024
• Subjects: Aged; Albuminuria - drug therapy; Cohort Studies; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Disease Progression; Female; Glomerular Filtration Rate - drug effects; Humans; Kidney Failure, Chronic - mortality; Male; Middle Aged; Renal Insufficiency, Chronic - drug therapy; Renal Insufficiency, Chronic - mortality; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; mortality; albuminuria; chronic kidney disease; type 2 diabetes; end‐stage kidney disease; sodium‐glucose transporter 2 inhibitors

Clinical trials have shown the kidney-protective benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i). However, their real-world impact, particularly across varying levels of albuminuria, remains less well understood. This study aimed to evaluate the association of SGLT2i, compared with ot...